XITRONIX CORPORATION v. KLA-TENCOR CORPORATION [ORDER]
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Federal Circuit Summary
Before Prost, Newman, Mayer, Lourie, Dyk, Moore, O’Malley, Reyna, Wallach, Taranto, Chen, Hughes, and Stoll. Petition for panel rehearing and rehearing en banc.
Summary: Judge Newman dissents from the denial of a petition for rehearing en banc, to address the significance of the Federal Circuit’s determination that it does not have jurisdiction in an appeal over Walker Process antitrust claims.
The original Federal Circuit panel determined it did not have jurisdiction in an appeal over a Walker Process monopolization claim because the appealed issues of fraud and inequitable conduct did not present a substantial issue of patent law. KLA-Tencor petitioned for panel rehearing and rehearing en banc; both petitions were denied.
Judge Newman dissented. She believed the original decision was contrary to the statute governing Federal Circuit jurisdiction, as well as contrary to precedent and experience. Judge Newman disagreed that the Supreme Court’s decision in Gunn v. Minton (removing Federal Circuit jurisdiction from a state law legal malpractice action) removed Federal Circuit jurisdiction in Walker Process appeals. Judge Newman took issue with the original panel’s conclusion that “something more” was required to raise a substantial issue of patent law, without further explanation as to what would qualify as “something more.” Judge Newman cited en banc Federal Circuit precedent establishing that the Federal Circuit has exclusive jurisdiction over appeals involving antitrust aspects of Walker Process appeals. Judge Newman stressed that because the panel decision is contrary to the weight of authority, and changes what had been a stable jurisdictional path in Walker Process appeals, at a minimum, en banc review should be required.
Judge Lourie also dissented, without opinion.
This case is: XITRONIX CORPORATION v. KLA-TENCOR CORPORATION [ORDER]
Written by: Ashley C. Morales and Mark Kachner
Edited by: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…